TY - JOUR
T1 - Metal nanoparticles restrict the growth of protozoan parasites
AU - Adeyemi, Oluyomi Stephen
AU - Molefe, Nthatisi Innocentia
AU - Awakan, Oluwakemi Josephine
AU - Nwonuma, Charles Obiora
AU - Alejolowo, Omokolade Oluwaseyi
AU - Olaolu, Tomilola
AU - Maimako, Rotdelmwa Filibus
AU - Suganuma, Keisuke
AU - Han, Yongmei
AU - Kato, Kentaro
N1 - Funding Information:
The authors acknowledge the International Foundation for Science (IFS) Grant F/5672 and the Japan Society for the Promotion of Science Fellowship.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/11/12
Y1 - 2018/11/12
N2 - The Trypanosoma and Toxoplasma spp, are etiological agents of diseases capable of causing significant morbidity, mortality and economic burden, predominantly in developing countries. Currently, there are no effective vaccines for the diseases caused by these parasites; therefore, therapy relies heavily on antiprotozoal drugs. However, the treatment options for these parasitic diseases are limited, thus underscoring the need for new anti-protozoal agents. Here, we investigated the anti-parasite action of nanoparticles. We found that the nanoparticles have strong and selective in vitro activity against T. b. brucei but moderate in vitro activity against T. congolense and T. evansi. An estimation of the in vitro anti-Trypanosoma efficacy showed that the nanoparticles had ≥200-fold selective activity against the parasite versus mammalian cells. Moreover, the nanoparticle alloys moderately suppressed the in vitro growth of T. gondii by ≥60%. In our in vivo study, the nanoparticles appeared to exhibit a trypanostatic effect, but did not totally suppress the rat parasite burden, thereby failing to appreciably extend the survival time of infected animals compared with the untreated control. In conclusion, this is the first study to demonstrate the selective in vitro anti-Trypanosoma action of nanoparticles and thus supports the potential of nanoparticles as alternative anti-parasitic agents.
AB - The Trypanosoma and Toxoplasma spp, are etiological agents of diseases capable of causing significant morbidity, mortality and economic burden, predominantly in developing countries. Currently, there are no effective vaccines for the diseases caused by these parasites; therefore, therapy relies heavily on antiprotozoal drugs. However, the treatment options for these parasitic diseases are limited, thus underscoring the need for new anti-protozoal agents. Here, we investigated the anti-parasite action of nanoparticles. We found that the nanoparticles have strong and selective in vitro activity against T. b. brucei but moderate in vitro activity against T. congolense and T. evansi. An estimation of the in vitro anti-Trypanosoma efficacy showed that the nanoparticles had ≥200-fold selective activity against the parasite versus mammalian cells. Moreover, the nanoparticle alloys moderately suppressed the in vitro growth of T. gondii by ≥60%. In our in vivo study, the nanoparticles appeared to exhibit a trypanostatic effect, but did not totally suppress the rat parasite burden, thereby failing to appreciably extend the survival time of infected animals compared with the untreated control. In conclusion, this is the first study to demonstrate the selective in vitro anti-Trypanosoma action of nanoparticles and thus supports the potential of nanoparticles as alternative anti-parasitic agents.
KW - Chemotherapy
KW - infectious diseases
KW - nanomedicine
KW - trypanosomosis
UR - http://www.scopus.com/inward/record.url?scp=85050514325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050514325&partnerID=8YFLogxK
U2 - 10.1080/21691401.2018.1489267
DO - 10.1080/21691401.2018.1489267
M3 - Article
C2 - 30033773
AN - SCOPUS:85050514325
SN - 2169-1401
VL - 46
SP - S86-S94
JO - Artificial Cells, Nanomedicine and Biotechnology
JF - Artificial Cells, Nanomedicine and Biotechnology
IS - sup3
ER -